19Jun 2025
Semaglutide Lowers Stroke Risk More Than Empagliflozin in T2DM

Semaglutide Lowers Stroke Risk More Than Empagliflozin in T2DM

In a matched analysis of 15,798 patients, semaglutide reduced the risk of stroke (HR 0.62) compared to empagliflozin, with modest trends favoring semaglutide for MI and death. Dulaglutide showed no significant advantage over empagliflozin. At 3 years, the primary composite outcome occurred in 5.9% (semaglutide) vs. 6.9% (empagliflozin). These findings support semaglutide’s role in cardiovascular risk management in type 2 diabetes.

  • #endo-diabetology

Like

Save

Share